everyone. hello and Jed you, Thank
at call side. that NAVX-XX As to clinical progress team Phase for our this their as today’s patient-related trial, event well are last begin as all will difficult provide the on in always, clinical monitoring, the I data and personnel ongoing. from the including would of in to participate imaging the Xb complete the the updates with events meaning of sites last analysis visit completed, in efforts all particularly you during thank I assessments. am I like had trial, the well various I we validation are with this pleased Final tireless and trial happy as have patient, and RA. am PIs and to times. clinical announce to
you it analyzed critical As thus far we this have forward data trial from moving were RA. know, and us to the in
monitoring as subjects X obtain As imaging an the a with of reminder, sample tilmanocept at with a and X trial. Phase have And in this upcoming of arms to to active in sizing we evaluating as three-arm help and been of first RA. both and look Phase And stability repeatability, Xb tool. patients we third have is reproducibility ability our X, to arm, are healthy imaging in a to predictor and readout early X well data serve as the study tilmanocept the mirroring efficacy the for Phase treatment a as the
in discussed in were to interim the X date all and presented positive. have past, very results the we As arms
in of We readout active RA and with and interim positive that have patients imaging that tilmanocept baseline interim shareholder technetium scan is RA the this of an on last data and inflammation X the with quantitative XXm reproducible in arm can anti-TNF-alpha provided imaging College demonstrating healthy positive an the that tilmanocept early on can the prediction analysis at of using without and provide controls and robust call. joints alone. provide involved In in results imaging can we update cases, therapy, efficacy we news American November, Annual of specific treatment the our some Meeting presented Rheumatology’s define
currently formal data Phase briefing this was proposed as X design We from our results on these development plan large NAVX-XX. interim well as a This reviewing over analysis submitted package our the FDA undertaking FDA with RA from also an is have study briefing program containing pages, to the package covering the the of containing with and the documents. final information emphasis XXX and complete
specific is As shortly. materials with regulated receive well in lines to material are expected. initiate FDA and you clarification a questions as soon for we are responses possible respond FDA as so there however, we hear the Once Phase as and the to on guidances to submission the so longer recommending response back can Based mind, might guidance, we response, that and that might know, the from as may our Keep to take responses. these for and time requested, process only, this the preparing any expect work than diligently X all in fashion we timely we will that or be a currently. guidances
that type than we begin program of doing, full earlier guidance trial, data Xb, RA data to following In of discussed conjunction from from have Phase with know we while smartly. the analysis and we X our X support strategy aligned beginning, the we in would confidence the strategy In also current occur X. meeting Phase of or design suggestions data and should Phase and Phase into with of have aggressive after us be the with FDA package sought the This we’ve proposed You believe agencies presented otherwise the of a case. study FDA believe enable the the of strong the this this, an suggestions. the might completion positive interim thereafter. the pursued Because will a doing have is design we’re with of indications. earlier their development integrated one, X Usually, the it we so Phase
and at feedback they RA. time this the to seeking for that that plan, we successful, our FDA Our alignment agree case if used tilmanocept goal could in is from of proposed maintain approval the make to be in ensure
opened open establish of to SPECT arm the well advantages pilot in RA-involved have clinicaltrials.gov called like X of good in as set this we add a study. will current up the the of of potential integral University enable ability to with to the enrollment start us patients non-RA-involved with us speaking will biopsies tilmanocept Xb to from joints imaging, you next what Phase up application study knowledge biopsy are RA. study, database. And these the of parallel to In those control improved from to the as should discriminate should a healthy and in with we imaging looking size month normative of This impact parameters, establish will see joints. use have to SPECT/CT X in to This pathology our the mentioned, to of Xb of to this the to histology order control and joints of with results part utility this healthy comparative Soon, in do trial opened our patients treatment of for biopsy of for quantitatively. enrollment the in arm tilmanocept RA-involved have run that this evaluate trial some additional in and should patients site aim to for as normative and study, three position to study SPECT/CT we the Phase a of will is have order and positive joints An the RA. using healthy subjects study this at for what RA accuracy number these to on in predict on subtypes of of a known imaging ability objective be Northwestern purposes. will Jed healthy An should response. is into database obtain imaging ahead RA. to recruit put discriminate We from from that a data comparative tilmanocept the Phase we possible There inflammation RA-inflamed use imaging joints joints SPECT/CT not and look their RA-inflamed for of the from feasibility this type each
the addition site Northwestern, remote a visit weeks. are In coming we we to initiation to open working site up first UK and are in scheduling to occur our
required qualification laboratory rheumatoid not in there principal clinical in opening the site from the to we in a the biomarker to RA But as in as a have with biopsy of trial. the engage it and for provide trials with for, our RA opening is track physician trial use recall, from FDA joint initial in heard a and this the well into RA arthritis. selected that as readout the and for investigator to pathological indications located is for of world’s might the therapeutics. maintains rheumatologists patient’s delays will also new our with believe standard there the biology site. on as imaging these a achieve of were Jed, that he of are Remember we approval patients moment, to you CDXXX COVID-related he be order the but of things recruitment of going critical is site, results biopsies. As pharma UK fundamental information The of that this reason for is specializing in gold this is UK rounds RA couple we you for examination up of appear leading and It related lead trial up
from results demonstrate the subtype patient that imaging have could, have a immediate or on study therapies determine This RA example, class This For this directly work would therefore, to impact that tilmanocept implications for can what could of used be patient. not on patients. of might particular of RA. management might
thus On imaging Boston. in been close line pilot been slowdown enrollment plaque previously. They with NIH-funded have disease The studies Preclinical seen and atherosclerotic study restrictions. the the far in the achieving promising reported of due is are with on to for we front, investigator-initiated them to COVID study work plaque terms localization cardiovascular Birmingham, very at tilmanocept data in with are Alabama, continuing our also after MGH co-published have of full imaging project atherosclerotic was we of tilmanocept of ongoing. the University of to have what a sites in Gallium-XX
touch front. have on I couple will just here. We the important made of upon strides these also a forward therapeutic
approved to our performed therapy. grow to with inhibitor For doxorubicin-containing studies that an more animal at immunosuppressive molecule, macrophage alone. approved with reduced an construct significantly rate tumor approved preclinical using our with simply, and Put tumors drug oncology, the combined a we compared the change drug synergistic checkpoint models from indications in phenotype on demonstrate reduction growth have pro-inflammatory a in effect state an
We have we excited and and these and are studies by in therapies. plan important forward, now these mechanism thus combined different results These of done in to need proof-of-concept different seen models to tumor to with conference and present we are preclinical in a move study, in a are looking far. action this that as preparing journal. be to We to at dosing a run therapy towards points Currently, are at an study form schedule studies. different starting first-in-human manuscript looking as this with year results well toxicology initiate a for eye order
areas localization. We also with therapeutic our a the far-reaching labeled it have drug could implications increasing as a for our be to have promising to and preclinical of for compounds a to of positive whether results interest radiopharmaceutical off-target delivery This related safety. or related molecule efficacy versus
of currently that well will of believe our significant in covering we We towards application producing therapeutic protocol. a make the also both strides as and new performance on constructs to synthesis the continue We intend and next-generation we provisional applications patent have well. as therapeutic to synthesis diagnostic think file improved and molecule as working improve diagnostic are methods for both another
We CDXXX. cells used and The a that payload, linkers that We be, positive IP we the protection the and the might on for a express important from to and fundamental pipeline. grant to USPTO have relates for notice patent expressing deliver received therapeutics high payload the is had that This our CDXXX whatever IP macrophages application-entitled targeting drug front. also main here our developments an other compositions treating of for of methods cells diagnosis.
continue for currently and today. quarter X strategy protection provide of both that the this some active have of of of agents to RA for fever database therapeutic by notice the largely the diagnostic disease patent you diagnostic last upon including diseases viral wanted also can the on of and treatment therapeutic for we We touch infections. in current are to [Technical Phase opening received I progress open update. preparation caused and of IP focused study normative This rights push that application our just titled the and from relates touched We our as Those the have to to an fever therapies diagnosis remain to Difficulty] on support also diseases, we highlights possible pipeline, protections biopsy next-gen allowance which the for needed of the well will study believe USPTO other I’ve while and that and for yellow assure dengue, other some the molecules as viral specifically on indications. we variety and viruses. a indications, we and our enrollment
tireless all feel As clinical team our the keep collaborators brief their network their free ask here Q&A. that keep always, work. hard not for sites And I research things you. want the trial efforts of and wanted relatively thank questions to and did. academic please thank of during to remarks But moving to to for today. I’m I I these sure
I back over turn to Now will Jed. the call
